Salmedix (Biotechnology, Health Care) — Funding, Investors & Signals 2026

Salmedix

Pioneering advanced treatments for blood cancers, delivering innovative Phase II clinical trials with a focus on patient health and care

Founded 2000 Series C Total: $72.50M Biotechnology, Health Care

Founded in 2000 by David Kabakoff, Salmedix is a pioneer in oncology drug development, focusing on treatments for hematologic malignancies. The company's primary product, SDX-105, has been made available in Germany to address various blood cancers, and is currently undergoing Phase II clinical trials in the U.S. and Canada. Additionally, Salmedix has other clinical-stage product candidates, SDX-101 and SDX-102, which are in Phase II development, backed by substantial prior human clinical experience. The recent $45.00M Series C investment received on 19 October 2005 included prominent investors such as Novo Holdings, OrbiMed, H.I.G. Capital, Quilvest Capital Partners, Covera Ventures, and Cariden Technologies. The company's slogan, "Pioneering advanced treatments for blood cancers, delivering innovative Phase II clinical trials with a focus on patient health and care," embodies its commitment to revolutionizing the field of oncology and prioritizing patient well-being and care. With its base in San Diego, California, Salmedix is carving a niche for itself in the Biotechnology and Health Care industries.

Funding Stage	Amount	Investors	Lead Investors	Date
Series C	$45.00M	6	Cariden Technologies	19 Oct 2005
Series B	$27.50M	4	Alexandria Real Estate Equities	19 Jun 2002
Series A	Unknown	-		01 Jan 2001

Funding Stage

Amount

Investors

Lead Investors

Date

Series C

$45.00M

Cariden Technologies

19 Oct 2005

Series B

$27.50M

Alexandria Real Estate Equities

19 Jun 2002

Series A

Unknown

01 Jan 2001

FAQ About Salmedix

Pioneering advanced treatments for blood cancers, delivering innovative Phase II clinical trials with a focus on patient health and care

Salmedix was founded in 2000.

Salmedix operates in the following industries: Biotechnology, Health Care.

Salmedix has completed 3 funding rounds, raising a total of $72.50M. The latest funding stage is Series C.

Top alternatives and competitors to Salmedix include CellCentric, Toragen, Inc., BBB Therapeutics, Rexahn Pharmaceuticals, Geron Corporation. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Salmedix and CellCentric are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Salmedix

General Information

Track Salmedix

Discover More

About Salmedix

Funding Rounds & Investors (3)

Salmedix Alternatives & Competitors

FAQ About Salmedix

Don't just browse. Track.